Today’s Research Reports on GeneNews Limited, Knight Therapeutics Inc., Revive Therapeutics Ltd. and Fennec Pharmaceuticals Inc.
NEW YORK, NY / ACCESSWIRE / January 5, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://rdinvesting.com and get exclusive access to our numerous research reports and market updates.
RDI has Initiated Coverage Today on:
GeneNews Limited
https://rdinvesting.com/news/?ticker=GEN.TO
Knight Therapeutics Inc.
https://rdinvesting.com/news/?ticker=GUD.TO
Revive Therapeutics Ltd.
https://rdinvesting.com/news/?ticker=RVV.V
Fennec Pharmaceuticals Inc.
https://rdinvesting.com/news/?ticker=FRX.TO
GeneNews stock moved 2.78% lower Thursday, to close the day at $0.17. The stock recorded a trading volume of 809,972 shares, which was above its three months average volume of 696,245 shares. In the last year, GeneNews shares have traded in a range of 0.08 - 0.53. The share price has gained 118.75% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $0.15 is greater than its 200-day moving average of $0.13. Shares of GeneNews have fallen approximately 22.22 percent year-to-date.
Access RDI's GeneNews Limited Research Report at:
https://rdinvesting.com/news/?ticker=GEN.TO
On Thursday, shares in Knight Therapeutics Inc. recorded a trading volume of 285,428 shares, which was above the three months average volume of 207,417 shares. The stock ended the day 1.57% higher at 8.41. The stock is currently trading 23.55% below its 52-week high with a 52-week trading range of 7.51 - 11.00.The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $7.86 is below its 200-day moving average of $8.72. Shares of the company are trading at a Price to Earnings ratio of 67.28. Shares of Knight Therapeutics Inc. have gained approximately 35.03 percent year-to-date.
Access RDI's Knight Therapeutics Inc. Research Report at:
https://rdinvesting.com/news/?ticker=GUD.TO
Revive Therapeutics stock jumped 7.95% Thursday, to close the day at $0.47. The stock recorded a trading volume of 4,247,980 shares, which was above its three months average volume of 961,209 shares. In the last year, Revive Therapeutics shares have traded in a range of 0.11 - 0.51. The share price has gained 352.38% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $0.29 is greater than its 200-day moving average of $0.21. Shares of Revive Therapeutics have gained approximately 14.46 percent year-to-date.
Access RDI's Revive Therapeutics Ltd. Research Report at:
https://rdinvesting.com/news/?ticker=RVV.V
On Thursday, shares in Fennec Pharmaceuticals recorded a trading volume of 360 shares, which was below the three months average volume of 2,072 shares. The stock ended the day 1.62% higher at 12.57. The share price has gained 419.42% from its 52-week low with a 52-week trading range of 2.42 - 16.23.The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $12.08 is greater than its 200-day moving average of $10.87. Shares of Fennec Pharmaceuticals have gained approximately 0.64 percent year-to-date.
Access RDI's Fennec Pharmaceuticals Inc. Research Report at:
https://rdinvesting.com/news/?ticker=FRX.TO
Our Actionable Research on GeneNews Limited (TSX:GEN.TO), Knight Therapeutics Inc. (TSX:GUD.TO), Revive Therapeutics Ltd. (TSXV:RVV.V) and Fennec Pharmaceuticals Inc. (TSX:FRX.TO) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
Address:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
Email:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: RDInvesting.com
